West Pharmaceutical Services Inc. (NYSE: WST) is among the most oversold S&P 500 stocks in 2025. Barclays analyst Luke Sergott initiated coverage on WST with an Equal Weight rating and a $245 price target, citing challenges in non-core areas impacting recent performance.

Sergott highlights issues in SmartDose and continuous glucose monitoring manufacturing affecting sentiment, despite their smaller size. He warns of potential disruption from the shift to oral GLP-1 treatments, impacting demand for West’s injectable delivery systems over time.

The HVP segment is seen as a key revenue driver for West, expected to grow by mid-single digits to high single digits long term. The company specializes in injectable drug delivery systems, high-performance packaging components, and innovative delivery technologies for pharmaceutical partners globally.

While acknowledging WST’s investment potential, Barclays believes some AI stocks offer greater upside with less downside risk. For more information on undervalued AI stocks and trends, check out their free report.

Read more at Yahoo Finance: Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks